A Phase IV Multicenter Trial to Evaluate the Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib and Its Companion Diagnostic Test in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) Patients
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 29 Aug 2017 Planned End Date changed from 1 Jul 2017 to 1 Jun 2018.
- 29 Aug 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Mar 2018.
- 10 Jun 2017 Biomarkers information updated